Integra Lifesciences Holdings (IART) Non-Current Debt (2009 - 2026)

Integra Lifesciences Holdings' Non-Current Debt history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Non-Current Debt rose 55.09% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 55.09% YoY), while the FY2025 annual figure was $1.7 billion, up 58.98% from the prior year.
• Non-Current Debt came in at $1.8 billion for Q1 2026 at Integra Lifesciences Holdings, up from $1.7 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $1.8 billion in Q1 2026 to a low of $733.1 million in Q4 2022.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt retreated 11.05% in 2022 and jumped 58.98% in 2025, its largest moves.
• Integra Lifesciences Holdings' Non-Current Debt stood at $733.1 million in 2022, then grew by 12.61% to $825.6 million in 2023, then jumped by 31.78% to $1.1 billion in 2024, then jumped by 58.98% to $1.7 billion in 2025, then gained by 1.2% to $1.8 billion in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $1.8 billion, $1.7 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison